altretamine

also known as Altretamina · Hexalen · Hexamethylmelamine · Hexastat · HMM · NSC-13875

Developed for: lymphoma · sarcoma
Investigated by: National Cancer Institute (NCI) · Roswell Park Cancer Institute

Regulatory milestones approvals, filings & regulatory actions · 1 recorded

Milestone	Jurisdiction	Brand	Indication	Date	Sentence it was read from
Approved	US (FDA)	HEXALEN	—	1990-12-26	fda.gov ↗

Trials 1

today

US approved 1990

NCT00002936 · Ph 1

19901991199219931994199519961997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 1	NCT00002936	Jul 1996 → Jan 2007	lymphoma, sarcoma	Roswell Park Cancer Institute	Completed	No outcome recorded

Evidence & citations 8 cited values

Every value below carries the sentence it was read from. 2 sources stand behind the page.

Field	Value	Cited text
Known as	altretamine	ClinicalTrials.gov intervention name — accepted as the source's own label NCT00002936 ↗
Known as	Altretamina	ChEMBL registry synonym — accepted as the source's own label CHEMBL1455 ↗
Known as	Hexalen	ChEMBL registry synonym — accepted as the source's own label CHEMBL1455 ↗
Known as	Hexamethylmelamine	ChEMBL registry synonym — accepted as the source's own label CHEMBL1455 ↗
Known as	Hexastat	ChEMBL registry synonym — accepted as the source's own label CHEMBL1455 ↗
Known as	HMM	“Patients are treated with altretamine (HMM) and etoposide for 2 weeks followed by 2 weeks of rest.” NCT00002936 ↗
Known as	NSC-13875	ChEMBL registry synonym — accepted as the source's own label CHEMBL1455 ↗
Modality	Small molecule	— CHEMBL1455 ↗